Vir Biotechnology (VIR) Cash from Investing Activities (2018 - 2026)

Vir Biotechnology has disclosed Cash from Investing Activities across 9 years of filings, most recently posting $11.8 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $11.8 million, down 90.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $195.4 million (down 67.31% YoY), and the FY2025 annual result was $310.4 million, down 37.85% from the prior year.
• Cash from Investing Activities came in at $11.8 million for Q1 2026 at Vir Biotechnology, down from $86.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $230.3 million in Q2 2023 to a low of -$662.6 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is $40.4 million (2025), against an average of -$12.2 million.
• Across the five-year window, Cash from Investing Activities tumbled 997.12% in 2022 and jumped 346.23% in 2025, its largest moves.
• Vir Biotechnology's Cash from Investing Activities stood at -$153.1 million in 2022, then soared by 31.56% to -$104.8 million in 2023, then jumped by 234.28% to $140.7 million in 2024, then sank by 38.43% to $86.7 million in 2025, then plunged by 86.34% to $11.8 million in 2026.
• The last three Cash from Investing Activities figures came in at $11.8 million (Q1 2026), $86.7 million (Q4 2025), and $40.4 million (Q3 2025), per Business Quant data.